News

The latest news and updates from Entrada Therapeutics

Filter By:

Entrada Therapeutics Appoints John F. Crowley to Board of Directors

BOSTON, Mass., June 19, 2019 – Entrada Therapeutics, a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced the appointment of John F. Crowley as an independent board member to the Company’s Board of Directors.

Read more
June 19, 2019

Entrada Therapeutics Appoints Mario Saltarelli, M.D., Ph.D., as Chief Medical Officer

BOSTON, Mass., March 19, 2019 – Entrada Therapeutics, a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced the appointment of Mario Saltarelli, M.D., Ph.D., as Chief Medical Officer.

Read more
March 19, 2019

Entrada Therapeutics Raises $59 Million Series A to Advance Intracellular Biologics Platform

BOSTON, Mass., Dec. 18, 2018 – Entrada Therapeutics, a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced it has raised $59 million in a Series A financing.

Read more
December 18, 2018